GlassScriptPhysician profile
Daryl Greenhall
NPI 1780283580
$2,193.87
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $628 · 2022: $820 · 2023: $579 · 2024: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $361.58 | 2021-2023 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $237.76 | 2021-2023 | Injectafer |
| Lucid Diagnostics INC. | $197.91 | 2021-2022 | |
| Abbvie INC. | $140.97 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.76 | 2021-2023 | |
| Baxter Healthcare | $115.13 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Dexcom, INC. | $106.96 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $88.72 | 2021-2023 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.03 | 2021-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $85.39 | 2022-2023 | |
| Pfizer INC. | $78.30 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $69.36 | 2021 | |
| Gilead Sciences, INC. | $63.67 | 2022-2023 | Epclusa |
| Medtronic, INC. | $57.49 | 2022-2023 | Intellis Adaptivestim |
| Mannkind Corporation | $48.66 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.34 | 2021-2022 | |
| Boston Scientific Corporation | $45.16 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $38.36 | 2022-2023 | Fasenra |
| Corcept Therapeutics | $35.25 | 2023 | Korlym |
| Insulet Corporation | $30.28 | 2023 | Omnipod |
| Phadia US INC. | $19.41 | 2023 | Immunocap |
| Otsuka America Pharmaceutical, INC. | $19.15 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.53 | 2022 | |
| Glaxosmithkline, LLC. | $15.55 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $13.92 | 2023 | Gvoke Hypopen |
| Amgen INC. | $13.22 | 2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $12.85 | 2021 | |
| Vistapharm, INC. | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Greenhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.